Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
- Merck & Co Inc (NYSE:MRK) has announced new data from Phase 2a trial evaluating islatravir for pre-exposure prophylaxis (PrEP) of HIV-1 infection in adults at low risk of contracting HIV-1.
- After 24 weeks, once-monthly oral islatravir was generally well tolerated versus placebo.
- Most adverse events (AEs) were mild, and there were no serious drug-related AEs in people who received islatravir.
- The levels of islatravir in peripheral blood mononuclear cells (PBMCs) also remained above the pre-specified efficacy PK threshold for PrEP at both doses studied (60 mg and 120 mg) eight weeks after the last study dose.
- These data were shared at the International AIDS Society Conference on HIV Science.
- Islatravir (MK-8591) is an investigational nucleoside reverse transcriptase translocation inhibitor.
- Price Action: MRK shares are up 0.14% at $77.16 during the premarket session on the last check Tuesday.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!